Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


PGEU sets out best practice on pharmacovigilance and risk minimisation

The Pharmaceutical Group of the European Union (PGEU) has published a new Best Practice Paper on Pharmacovigilance and Risk Minimisation.

Released on the same day that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) held its first-ever public hearing, on the epilepsy drug sodium valproate, the PGEU paper makes several recommendations on ways to increase medicines safety.

Several of the recommendations align to Royal Pharmaceutical Society policies, including access to shared electronic health records, greater collaboration between pharmacists and other healthcare professionals and expansion of new medicines services.

The report says that “more can be done by health policy makers and health systems payers to enhance the role of community pharmacists and their contribution to pharmacovigilance and patient safety activities”. The new paper has been drawn up as a “direct response” to this, and aims to collate and exchange best practice as well as raising awareness of pharmacists’ contribution to patient and medicines safety.

The paper also says that pharmacists should be told why a particular medication has been prescribed to allow for better reporting of adverse reactions from off-label prescribing and to help ensure that the most suitable therapy is provided. And it calls for continued collaboration between national pharmacy bodies, the PGEU and the EMA.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203631

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Medicines Agency building

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.